CRBU
NASDAQ
$1.62
Caribou Biosciences Inc (CRBU)
Caribou Biosciences Inc. is a pioneering biotechnology firm specializing in genome editing through its proprietary CRISPR technology, aimed at developing transformative therapies for genetic disorders and oncology. With a robust and diversified pipeline addressing significant unmet medical needs, the company is well-positioned to lead advancements in precision medicine. Caribou's strategic collaborations and unwavering commitment to research excellence underpin its mission to revolutionize treatment paradigms and improve patient outcomes, establishing its foothold as a key player in the biopharmaceutical sector.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $12 (+640.74%)
Market Cap
$168M
Free Cash Flow Yield
-60.86%
Beta (5Y)
1.85
Price Chart
Valuation
Market Cap$168M
P/S15.32
P/B1.70
Profitability
Total Revenue (TTM)$11M
Gross Profit (TTM)-$81M
EBITDA-$129M
Operating Margin-1096%
EPS-$1.41
Financial Health
Free Cash Flow Yield-60.86%
Growth & Risk
Revenue 5Y CAGR-4.29%
Beta (5Y)1.85
Sharpe Ratio0.18